Physician profile
Yolanda Chik
NPI 1417162058
$1,898.51
in general payments reported to CMS, 2019-2025
22 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $125 · 2021: $250 · 2022: $277 · 2023: $417 · 2024: $479 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $600.03 | 2019-2021 | |
| Ceribell, INC. | $267.33 | 2023-2024 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Biohaven Pharmaceutical Holding Company Ltd. | $242.55 | 2022 | |
| Ucb, INC. | $226.10 | 2023-2024 | Briviact, Rystiggo |
| Abbvie INC. | $83.72 | 2023-2025 | Duopa |
| Tanabe Pharma America, INC. | $50.35 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.69 | 2023-2024 | Hyqvia |
| Neurelis, INC. | $41.55 | 2023-2024 | Valtoco |
| Livanova USA, INC. | $34.78 | 2022 | |
| Argenx US, INC. | $34.14 | 2023 | Vyvgart |
| Neurocrine Biosciences, INC. | $31.56 | 2025 | |
| Horizon Therapeutics Plc | $29.23 | 2023 | Uplizna |
| Biogen, INC. | $28.13 | 2024 | Avonex, Tysabri, Vumerity |
| Csl Behring | $27.55 | 2025 | Hizentra |
| Lilly USA, LLC | $27.20 | 2023 | Reyvow, Emgality |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $24.78 | 2023 | Qutenza |
| Alexion Pharmaceuticals, INC. | $22.00 | 2025 | Ultomiris |
| Banner Life Sciences, LLC | $21.85 | 2023 | |
| Eisai INC. | $18.91 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.58 | 2023 | Gliadel |
| Upsher-Smith Laboratories LLC | $15.48 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Chik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.